|
1
|
The Editorial Board of the Cancer
Statistics in Japan: Cancer Statistics in Japan 2015Foundation for
Promotion of Cancer Research. National Cancer Center; Tokyo: 2016,
https://ganjoho.jp/data/reg_stat/statistics/brochure/2015/cancer_statistics_2015.pdfMarch
30–2016
|
|
2
|
Welch HG, Prorok PC, O'Malley AJ and
Kramer BS: Breast-cancer tumor size, overdiagnosis and mammography
screening effectiveness. N Engl J Med. 375:1438–1447. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fentiman IS: The dilemma of in situ
carcinoma of the breast. Int J Clin Pract. 55:680–683.
2001.PubMed/NCBI
|
|
4
|
Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN,
Dupont E, Hutson L, Peltz E, Whitehead G, Reintgen D and Cantor A:
Importance of lymphatic mapping in ductal carcinoma in situ (DCIS):
Why map DCIS? Am Surg. 67:513–519. 2001.PubMed/NCBI
|
|
5
|
Brennan ME, Turner RM, Ciatto S,
Marinovich ML, French JR, Macaskill P and Houssami N: Ductal
carcinoma in situ at core needle biopsy: Meta-analysis of
underestimation and predictors of invasive breast cancer.
Radiology. 260:119–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grady WM and Tewai M: The next thing in
prognostic molecular markers: microRNA signatures of cancer. Gut.
59:706–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Graveel CR, Calderone HM, Westerhuis JJ,
Winn ME and Sempere LF: Critical analysis of the potential for
microRNA biomarkers in breast cancer management. Breast Cancer
(Dove Med Press). 7:59–79. 2015.PubMed/NCBI
|
|
8
|
Shimomura A, Shiino S, Kawauchi J,
Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S,
Shiizu C, et al: Novel combination of serum microRNA for detedting
brest cnacer in the early stage. Cancer Sci. 107:326–334. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ge Q, Zhou Y, Lu J, Bai Y, Xie X and Lu Z:
miRNA in plasma exosome is stable under different storage
conditions. Molecules. 19:1567–1575. 2014. View Article : Google Scholar
|
|
10
|
Valadi H, Ekström K, Bossios A, Sjöstrand
M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Simons M and Raposo G: Exosomes-vesicular
carriers for intercelluar communication. Curr Opin Cell Biol.
21:575–581. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hannafon BN and Ding WQ: Intercelluar
communication by exosome-derived microRNAs in cancer. Int J Mol
Sci. 14:14240–14269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogata-Kawata H, Izumiya M, Kurioka D,
Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H,
et al: Circulating exosomal microRNAs as biomarkers of colon
cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joyce DP, Kerin MJ and Dwyer RM:
Exosome-encapsulated microRNAs as circulating biomarkers for breast
cancer. Int J Cancer. 139:1443–1448. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hannafon BN, Trigoso YD, Calloway CL, Zhao
YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ:
Plasma exosome microRNAs are indicative of breast cancer. Breast
Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurashige J, Hasegawa T, Niida A,
Sugimachi K, Deng N, Mima K, Uchi R, Sawada G, Takahashi Y, Eguchi
H, et al: Integrated molecular profiling of human gastric cancer
identifies DDR2 as a potential regulator of peritoneal
dissemination. Sci Rep. 6:223712016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dejima H, Iinuma H, Kanaoka R, Matsutani N
and Kawamura K: Exosomal microRNA in plasma as a non-invasive
biomarker for the recurrence of non-small cell lung cancer. Oncol
Lett. 13:1256–1263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsukamoto M, Iinuma H, Yagi T, Matsuda K
and Hashiguchi Y: Circulating exosomal MicroRNA-21 as a biomarker
in each tumor stage of colorectal cancer. Oncology. 92:360–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J Pathol. 223:307–317.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Osako T, Iwase T, Ushijima M, Horii R,
Fukami Y, Kimura K, Matsuura M and Akiyama F: Incidence and
prediction of invasive disease and nodal metastasis in
preoperatively diagnosed ductal carcinoma in situ. Cancer Sci.
105:576–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan MY and Lim S: Predictors of invasive
breast cancer in ductal carcinoma in situ initially diagnosed by
core biopsy. Asian J Surg. 33:76–82. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim J, Han W, Lee JW, You JM, Shin HC, Ahn
SK, Moon DG, Cho N, Moon WK, Park IA and Noh DY: Factors associated
with upstaging from ductal carcinoma in situ following core needle
biopsy to invasive cancer in subsequent surgical excision. Breast.
21:641–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshikawa M: Sentinel node biopsy in
patients diagnosed with ductal carcinoma in situ preoperatively.
Japanese Soc Sentinel Node Navigation Surg. 18:452016.
|
|
24
|
Kodahl AR, Lyng MB, Binder H, Cold S,
Gravgaard K, Knoop AS and Ditzel HJ: Novel circulating microRNA
signature as a potential non-invasive multi-marker test in
ER-positive early-stage breast cancer: A case control study. Mol
Oncol. 8:874–883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang L, Li F, Deng P and Hu C:
MicroRNA-223 promotes tumor progression in lung cancer A549 cells
via activation of the NF-κB signaling pathway. Oncol Res.
24:405–413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pinatel EM, Orso F, Penna E, Cimino D,
Elia AR, Circosta P, Dentelli P, Brizzi MF, Provero P and Tavern D:
miR-223 is a coordinator of breast cancer progression as reveraled
by bioinformatics predictions. PLoS One. 9:e848592014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun X, Li Y, Zheng M, Zuo W and Zheng W:
MicroRNA-223 increases the sensitivity of triple-negative breast
cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1.
PLoS One. 11:e01627542016. View Article : Google Scholar : PubMed/NCBI
|
